International projects

International projects

logo isidore

Program: HORIZON
Name of the project: 
Integrated Services for Infectious Disease Outbreak Research
Project acronym: ISIDORe
Duration of the project: 1. 2. 2022 – 31. 7. 2025
Project website: LINK

The consortium of ISIDORe project, HORIZON Research and Innovation Action supported under the call – HORIZON-INFRA-2021-EMERGENCY-02 (Grant agreement ID 101046133), is made of the capacities of European ESFRI infrastructures and coordinated networks that assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials.

By giving scientists access to the whole extent of its state-of-the-art facilities, cutting-edge services, advanced equipment and expertise, in an integrated way and with a common goal, it will accelerate the generation of new knowledge and intervention tools to enhance Europe’s capacity for controlling emerging and epidemic infectious diseases, starting with the COVID-19 pandemic.

logo vaccelerate

Program: H2020
Name of the project: 
VACCELERATE – European Corona Vaccine Trial Accelerator Platform
Project acronym: VACCELERATE
Duration of the project: 28. 1. 2021 – 27. 1. 2025
Project website: LINK

VACCELERATE project, H2020 Research and Innovation action supported under the call – H2020-IBA-SC1-CORONAVIRUS-2020-4 (Grant agreement ID 101037867), is a clinical research network for the coordination and conduct of COVID-19 vaccine trials comprised of academic institutions from all over Europe. The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct.

VACCELERATE offers expertise, services, resources and solutions to speed up existing and upcoming development programmes as well as market authorisations for new vaccines and vaccination strategies. The network serves as a single entry-point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 and 3 trials in Europe.

logo EVAg

Program: H2020
Name of the project: 
European Virus Archive GLOBAL
Project acronym: EVA-GLOBAL
Duration of the project: 1. 1. 2020 – 30. 9. 2024
Project website: LINK

EVA-GLOBAL project, H2020 Research and Innovation action supported under the call – H2020-INFRAIA-2019-1 (Grant agreement ID 871029), gathers 38 academic institutions at the forefront of human, animal and plant research in Virology, associated with key Non-Governmental Organisations including WHO and OIE. This project is built on the strong foundations constituted by two previous EVA (2009-2014), FP7 and EVAg (2014-2019), H2020 projects. This unique advanced international community aims at becoming the most responsive network to improve the control of emerging or re-emerging virus outbreaks at the global level.

EVA-GLOBAL is conceived to be an open access entity aiming at developing synergies and complementary capabilities in such a way to offer an improved access to the researchers. Through this new ambitious project, EVA-GLOBAL will become the largest virtual virus collection for human, animal and plant viruses.

Program: HORIZON
Name of the project:
Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
Project acronym: A4L_BRIDGE
Duration of the project: 1. 3. 2024 – 29. 2. 2028
Project website: LINK

A4L_BRIDGE project, HORIZON Coordination and support action supported under the call – HORIZON-WIDERA-2023-ACCESS-03 – European Excellence Initiative (Grant agreement ID 101136453), builds on previous successful H2020 projects – Alliance4Life (2018-2019) and A4L_ACTIONS (2021-2024). Alliance4Life is a bottom-up initiative of twelve leading life science institutions from eleven EU-13 countries that aims at closing the divide in European health research and innovation (R&I). With the A4L_BRIDGE project, the alliance focuses on a broader implementation of the successfully piloted strategic changes toward enhanced attractiveness, competitiveness, and innovation strength, and newly also addresses excellence in higher education.

The project aims to enhance scientific collaboration by establishing a Virtual Research Centre that connects various research groups. It will lay the groundwork for initial research projects to evolve into projects for Horizon Europe. The project will also develop educational programmes catering to all career stages, including mentoring, e-learning, and international internships. Additionally, it will promote knowledge transfer and organise events for end-users of health research outcomes.

Program: HORIZON

Name of the project: Zoonoses Emergence across Degraded and Restored Forest Ecosystems

Project acronym: ZOE

Duration of the project: 1. 1. 2024 – 31. 12. 2027

Project website: LINK

ZOE project, HORIZON Research and Innovation Action supported under the call – HORIZON-CL6-2023-BIODIV-01 (Grant agreement ID 101135094), will carry out innovative research and establish collaborations across an interdisciplinary consortium with expertise in geography, geobotanics, ecology, virology, immunology, epidemiology, sociology, psychology, anthropology and science dissemination from seven EU and four American countries.

Focusing on tropical biodiversity hotspots and temperate regions impacted by deforestation and related land use changes, the project will dissect the connections between ecosystem degradation, biodiversity loss and the emergence of zoonotic diseases. The researchers will use cutting-edge technologies and community engagement to inform our understanding of these connections. Furthermore, they will propose means of mitigating the escalating risks to environmental health and human well-being.

Program: HORIZON

Name of the project: Comprehensive Cancer Infrastructures 4 Europe

Project acronym: CCI4EU

Duration of the project: 1. 5. 2023 – 30. 4. 2026

Project website: LINK

CCI4EU project, HORIZON Coordination and support action supported under the call – HORIZON-MISS-2022-CANCER-01 (Grant agreement ID 101103746), is a European initiative aiming to help Member States and Associated Countries to develop a cancer care programme with an inclusive approach tailored to each nation’s baseline status, fostering increased integration between research and care.

While comprehensive cancer centres and networks have the potential to enhance care, research and education, the developmental levels of these centres vary widely. Addressing this issue, a European initiative through a capacity-building programme aims to alleviate disparities, also in the context of other actions ongoing, such as CRANE, JANE and UNCAN. The project will maximize impact by bridging with the work of ongoing EU cancer research projects.

Program: HORIZON

Name of the project: Alzheimer’s Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe

Project acronym:ADDIT-CE

Duration of the project: 1. 1. 2023 – 31. 12. 2026

Project website: LINK

ADDIT-CE project, HORIZON Coordination and support action supported under the call – HORIZON-WIDERA-2022-ACCESS-04 – Excellence Hubs (Grant agreement ID 101087124), focuses on addressing the fragmented implementation of modern Alzheimer’s disease (AD) diagnostics in clinical practice in Czechia and Slovakia. The project will support the cooperation between academia, business, government and civil society. The partnership is expected to strengthen research and innovation in the field of AD diagnostics and introduce novel technologies into AD clinical management.

ADDIT-CE will help design a national plan for combatting dementia, and will be widely disseminated to end users and society. ADDIT-CE will join forces of the involved ecosystems to revolutionise diagnostic approaches in both countries and continue to serve society even after the project’s completion.

Program: HORIZON

Name of the project: Fostering a European Research Area for Health Research

Project acronym: ERA4Health

Duration of the project: 1. 11. 2022 – 31. 10. 2029

Project website: LINK

ERA4Health project, HORIZON COFUND action supported under the call – HORIZON-HLTH-2022-DISEASE-03 (Grant agreement ID 101095426), is a European partnership that bring together partners and funding organization from different countries with the common goal of fostering high-impact translational research for addressing public health needs.

The project will increase transnational collaborative research funding for priority areas by creating a funding body for joint programming. It will focus on tackling diseases, reducing disease burden, improving public healthcare systems, and strengthening disease prevention and health promotion. ERA4Health will support relevant medical research, improve the use of health technologies, build capacity, in particular in conducting investigator initiated clinical studies at EU scale, and implement responsible research and innovation practices.

OTHER SOLVED PROJECTS IN BMC SAS

ProgramName of the projectProject acronymDuration of the projectProject website
HORIZONAlliance4Life Bridging the Research and Innovation Gap in Life SciencesA4L_BRIDGE1. 3. 2024 – 29. 2. 2028https://alliance4life.ceitec.cz/
HORIZONZoonoses Emergence across Degraded and Restored Forest EcosystemsZOE
1. 1. 2024 – 31. 12. 2027https://www.zoe-project.eu/
HORIZONCOMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPECCI4EU
1. 5. 2023 – 30. 4. 2026https://cci4eu.eu/
HORIZONAlzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central EuropeADDIT-CE
1. 1. 2023 – 31. 12. 2026https://addit-ce.ceitec.cz/
HORIZONFostering a European Research Area for Health ResearchERA4Health
1. 11. 2022 – 31. 10. 2029https://era4health.eu/
HORIZONEnabling the next generation in search of blood cancer curesCarrerasPathfinder1. 9. 2024 – 31. 8. 2029https://carreraspathfinders.eu/
HORIZONNanobiotechnologies for Innovative Therapeutic Approaches for CancerNANOBIO4CAN1. 11. 2023 – 31. 10. 2028https://nanobio4can.net/
COST
European Network for Sigma-1 Receptor as a Therapeutic OpportunitySIGMA-1EUROPE25. 10. 2024 – 24. 10. 2028https://www.cost.eu/actions/CA23156/
COST
International networking on in vitro colon models simulating gut microbiota mediated interactionsINFOGUT9. 10. 2024 – 8. 10. 2028https://www.cost.eu/actions/CA23110/
HORIZONFCAECC Fellowship programme for talented researchers in cancerAECC Talent1. 9. 2023 – 31. 8. 2028https://aecctalent.com/
COST
Precision medicine in biliary tract cancerPrecision-BTC-Network9. 10. 2023 – 8. 10. 2027https://precision-btc.eu/
COST
Wildlife Malaria NetworkWIMANET28. 9. 2023 – 27. 9. 2027https://wimanet-science.github.io/web/
ERANET - TRANSCAN-3 (JTC 2023)Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic CancerREACH1. 9. 2024 – 31. 8. 2027https://transcan.eu/output-results/funded-projects/reach.kl
ERANET - NEURON JTC 2023Reward-stress interactions as neurobiological substrate for resilience and vulnerability in mental health and depression: A translational large-scale projectRESIST-D1. 1. 2024 – 31. 12. 2026https://www.era-learn.eu/network-information/networks/neuron-cofund2/neuron-cofund2-joint-call-2023/reward-stress-interactions-as-neurobiological-substrate-for-resilience-and-vulnerability-in-mental-health-and-depression-a-translational-large-scale-project
COST
Modelling immunotherapy response and toxicity in cancerIMMUNO-model2. 11. 2022 – 1. 11. 2026https://www.immuno-model.eu/
COST
Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol (PRAGMATICK)PRAGMATICK16. 11. 2022 – 17. 10. 2026https://pragmatick-action.eu/
COST
Identification of biological markers for prevention and translational medicine in pancreatic cancerTRANSPAN11. 10. 2022 – 10. 10. 2026https://transpan.eu/
COST
Translational control in Cancer European Network TRANSLACORE4. 10. 2022 – 3. 10. 2026https://translacore.eu/
COST
Information, Coding, and Biological Function: the Dynamics of LifeDYNALIFE2. 10. 2023 – 18. 9. 2026https://www.dynalife.eu/
COST
European Network for Skin Engineering and ModelingNETSKINMODELS15. 9. 2022 – 14. 9. 2026https://netskinmodels-cost.com/
COST
Genome Editing to Treat Humans DiseasesGenE-Humdi15. 9. 2022 – 14. 9. 2026https://www.genehumdi.eu/
ERANET - TRANSCAN-3 (JTC 2022)Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learningANGELA1. 9. 2023 – 31. 8. 2026https://www.era-learn.eu/network-information/networks/transcan-3/2nd-transcan-3-joint-call-2022/early-detection-of-esophageal-squamous-cell-carcinoma-with-the-cytosponge-coupled-with-molecular-biomarkers-and-machine-learning
COST
A sound proteome for a sound body: targeting proteolysis for proteome remodelingProteoCure1. 11. 2023 – 6. 10. 2025https://proteocure.eu/
ERA-NETResistance under treatment in breast cancerRESCUER1. 8. 2020 – 31. 5. 2024LINK
H2020Alliance for Life Sciences: From Strategies to Actions in Central and Eastern EuropeA4L_ACTIONS1. 5. 2021 – 30. 4. 2024https://alliance4life.ceitec.cz/
COSTDeterminants of Physical Activities in SettingsDE-PASS22. 7. 2020 – 21. 4. 2024LINK
EEA and Norway Grants Fund for Regional CooperationTBFVnet: surveillance and research on tick-borne flavivirusesTBFV1. 7. 2020 – 31. 1. 2024https://www.tbfvnet.eu/
ERA-NETTEmprature-responsive Nanogels for TArgeted delivery of miCroRNAs in wound heaLing and tissue rEgeneration applicationSTENTACLES1. 2. 2020 – 31. 1. 2024LINK
ERA-NETUNveiling the MEchanism(s) underlying the switch to mania during antidepressant treatment: The role of glutamateUNMET1. 7. 2019 – 31. 1. 2024LINK
HORIZONA Coordination and Support Action to prepare UNCAN.eu platform4.UNCAN.eu1. 9. 2022 – 30. 11. 2023https://uncan.eu/
H2020Tick-Virus Interactions Shape persistence and Transmission OF Flavivirus pathogen in tick vectorTVISTOFF1. 9. 2021 – 31. 8. 2023https://cordis.europa.eu/project/id/101030179
IAEAMolecular Markers for Biological Dosimetry in Radiation Oncology, Cancer Risk, Assesment and Optimizing Cancer Therapy19. 9. 2017 – 9. 7. 2023LINK
H2020Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcersVISION1. 10. 2019 – 30. 6. 2023https://www.sav.sk/
ERA-NETMetabolic therapy of heart failure: which role for B vitaminsHF-MetaB1. 4. 2020 – 31. 3. 2024LINK
ERA-NETEstablishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumorsNExT1. 9. 2019 – 31. 3. 2023LINK
COSTAedes Invasive MosquitoesAIM29. 1. 2020 – 5. 3. 2023LINK
COSTCancer Nanomedicine – from the bench to the bedsideNANO2CLINIC28. 9. 2018 – 27. 3. 2023LINK
COSTNew diagnostic and therapeutic tools against multidrug resistant tumorsSTRATAGEM11. 9. 2018 – 10. 9. 2022LINK
3rd Health ProgrammeInnovative Partnership for Action Against Cancer – iPAACiPAAC1. 4. 2018 – 31. 12. 2021LINK
COSTIn vitro 3-D total cell guidance and fitnessCellFit16. 3. 2017 – 15. 9. 2021LINK
ERA-NETInnovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene TherapyINNOCENT1. 1. 2017 – 30. 6. 2021LINK
COSTDrosophila salivary gland secretory proteins as tunable and biodegradable natural glueENBA1. 1. 2017 – 20. 4. 2021LINK
COSTMitochondrial mapping: Evolution - Age - Gender - Lifestyle - EnvironmentMITO-EAGLE1. 1. 2017 – 28. 2. 2021LINK
COSTThe Comet assay as a human biomonitoring toolhCOMET1. 4. 2016 – 11. 10. 2020LINK
ERA-NETMultiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapyintraMMclo1. 7. 2016 – 31. 7. 2020LINK
H2020European virus archive goes globalEVAg1. 4. 2015 – 31. 7. 2020LINK
H2020Life Science Alliance: Closing Research and Innovation Divide in the EUAlliance4Life1. 1. 2018 – 31. 12. 2019LINK
H2020High level Integrated Sensor for Nano Toxicity ScreeningHISENTS1. 4. 2016 – 31. 3. 2019LINK
COSTApplication of next generation sequencing for the study and diagnosis of plant viral diseases in agricultureFA14079. 3. 2015 – 8. 3. 2019LINK
FP7Clinical Development of Nitisinone for AlkaptonuriaDevelopAKUre1. 11. 2012 – 31. 1. 2019LINK
FP7Anti-tick Vaccines to Prevent Tick-borne Diseases in EuropeANTIDotE1. 12. 2013 – 30. 11. 2018LINK
ERA-NETMEchanisms of Lymphocytes TRansmigration Across the Blood Brain BarrierMELTRA – BBB1. 8. 2015 – 31. 7. 2018LINKA
ERA-NETDevelopment of galectin-based therapeutics for the treatment of hantaviral hemorrhagic feverGalhant1. 1. 2016 – 31. 12. 2017LINK
COSTAldosterone and Mineralocorticoid ReceptorADMIRE23. 11. 2016 – 30. 11. 2017LINK
H2020Building-up Centre of Excellence for advanced materials applicationCEMEA1. 6. 2015 – 31. 5. 2016LINK
COSTSustainable production of high-quality cherries for the European marketFA110415. 4. 2013 – 15. 4. 2016